May 2016, Vol. 5, No. 4 - National Comprehensive Cancer Network
The revised guideline (Version 2.2016) for the management of advanced melanoma, released by the National Comprehensive Cancer Network (NCCN), shows increasing appreciation for the use of immune checkpoint inhibitors and targeted agents, as more data establish these drug classes as having superior efficacy to traditional chemotherapy. “We’ve seen the approval [ Read More ]
May 2014, Vol 3, No 3 - Uncategorized
The BRAF inhibitor dabrafenib has been added as a category 1 recommendation for the primary treatment of BRAF-mutated metastatic melanoma in the latest version of the National Comprehensive Cancer Network (NCCN) guidelines. MEK inhibition with trametinib in BRAF-mutated melanoma was also added to the systemic therapy options for the treatment [ Read More ]
Copyright 2023. The Lynx Group, LLC. All Rights Reserved. Privacy Policy. Sitemap.
